耐喹诺酮类流感嗜血杆菌：环丙沙星、加替沙星、左氧氟沙星和莫西沙星突变选择窗的测定
Quinolone-resistant Haemophilus influenzae: determination of mutant selection window for ciprofloxacin, garenoxacin, levofloxacin, and moxifloxacin.
作者信息
Li Xinying, Mariano Noriel, Rahal James J, Urban Carl M, Drlica Karl
机构信息
Public Health Research Institute, 225 Warren St., Newark, NJ 07103, USA.
出版信息
Antimicrob Agents Chemother. 2004 Nov;48(11):4460-2. doi: 10.1128/AAC.48.11.4460-4462.2004.
Abstract
Stepwise selection of ciprofloxacin-resistant Haemophilus influenzae mutants produced first-, second-, third-, and fourth-step substitutions in GyrA (S84Y), ParC (S84R), GyrA (D88N), and ParC (E88K), respectively. Successive mutations raised the mutant selection window. The wild-type selection window for garenoxacin, levofloxacin, and moxifloxacin was also measured.
摘要
逐步筛选对环丙沙星耐药的流感嗜血杆菌突变体，分别在GyrA（S84Y）、ParC（S84R）、GyrA（D88N）和ParC（E88K）中产生了第一步、第二步、第三步和第四步替换。连续的突变提高了突变体选择窗口。还测定了加替沙星、左氧氟沙星和莫西沙星的野生型选择窗口。
相似文献
1
Quinolone-resistant Haemophilus influenzae: determination of mutant selection window for ciprofloxacin, garenoxacin, levofloxacin, and moxifloxacin.
Antimicrob Agents Chemother. 2004 Nov;48(11):4460-2. doi: 10.1128/AAC.48.11.4460-4462.2004.
2
Laboratory detection of Haemophilus influenzae with decreased susceptibility to nalidixic acid, ciprofloxacin, levofloxacin, and moxifloxacin due to GyrA and ParC mutations.
J Clin Microbiol. 2004 Mar;42(3):1185-91. doi: 10.1128/JCM.42.3.1185-1191.2004.
3
Emergence of high-level fluoroquinolone resistance in emm6 Streptococcus pyogenes and in vitro resistance selection with ciprofloxacin, levofloxacin and moxifloxacin.
J Antimicrob Chemother. 2009 May;63(5):886-94. doi: 10.1093/jac/dkp057. Epub 2009 Mar 11.
4
In vitro pharmacodynamics of moxifloxacin versus levofloxacin against 4 strains of Streptococcus pneumoniae: 1 wild type, 2 first-step parC mutants, and 1 pump mutant.
Diagn Microbiol Infect Dis. 2008 Feb;60(2):155-61. doi: 10.1016/j.diagmicrobio.2007.08.005. Epub 2007 Oct 29.
5
Fluoroquinolone-resistant Brucella melitensis mutants obtained in vitro.
Int J Antimicrob Agents. 2009 Sep;34(3):252-4. doi: 10.1016/j.ijantimicag.2008.12.013. Epub 2009 Feb 24.
6
Activities of different fluoroquinolones against Bacillus anthracis mutants selected in vitro and harboring topoisomerase mutations.
Antimicrob Agents Chemother. 2004 Aug;48(8):3024-7. doi: 10.1128/AAC.48.8.3024-3027.2004.
7
In vitro development of resistance to DX-619 and other quinolones in enterococci.
J Antimicrob Chemother. 2006 Dec;58(6):1268-73. doi: 10.1093/jac/dkl421. Epub 2006 Oct 24.
8
Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model.
Antimicrob Agents Chemother. 2003 Aug;47(8):2606-14. doi: 10.1128/AAC.47.8.2606-2614.2003.
9
The selection of resistance to and the mutagenicity of different fluoroquinolones in Staphylococcus aureus and Streptococcus pneumoniae.
Clin Microbiol Infect. 2005 Sep;11(9):750-8. doi: 10.1111/j.1469-0691.2005.01211.x.
10
Correlation between in vitro and in vivo activity of levofloxacin and moxifloxacin against pneumococcal strains with different susceptibilities to fluoroquinolones.
Int J Antimicrob Agents. 2006 Apr;27(4):294-9. doi: 10.1016/j.ijantimicag.2005.10.022. Epub 2006 Mar 9.
引用本文的文献
1
Genomic profiling of cefotaxime-resistant from Norway and Sweden reveals extensive expansion of virulent multidrug-resistant international clones.
Front Microbiol. 2025 Jul 29;16:1601390. doi: 10.3389/fmicb.2025.1601390. eCollection 2025.
2
Brief antibiotic use drives human gut bacteria towards low-cost resistance.
Nature. 2025 May;641(8061):182-191. doi: 10.1038/s41586-025-08781-x. Epub 2025 Apr 23.
3
The Drug-Specific Propensity Regarding the Acquisition of Fluoroquinolone Resistance in : An in vitro Challenge and DNA Mutation Analysis.
Infect Drug Resist. 2023 Sep 26;16:6357-6366. doi: 10.2147/IDR.S428383. eCollection 2023.
4
Molecular epidemiology and antibiotic resistance profiles of invasive from Norway 2017-2021.
Front Microbiol. 2022 Aug 29;13:973257. doi: 10.3389/fmicb.2022.973257. eCollection 2022.
5
Quinolone Resistance Is Transferred Horizontally via Uptake Signal Sequence Recognition in Haemophilus influenzae.
Antimicrob Agents Chemother. 2022 Feb 15;66(2):e0196721. doi: 10.1128/AAC.01967-21. Epub 2021 Dec 20.
6
Evaluation of Fluoroquinolone Resistance in Clinical Avian Pathogenic Isolates from Flanders (Belgium).
Antibiotics (Basel). 2020 Nov 12;9(11):800. doi: 10.3390/antibiotics9110800.
7
Soft sweep development of resistance in Escherichia coli under fluoroquinolone stress.
J Microbiol. 2019 Dec;57(12):1056-1064. doi: 10.1007/s12275-019-9177-5. Epub 2019 Sep 25.
8
Variation in Mutant Prevention Concentrations.
Front Microbiol. 2019 Jan 31;10:42. doi: 10.3389/fmicb.2019.00042. eCollection 2019.
9
Microbial virulence, molecular epidemiology and pathogenic factors of fluoroquinolone-resistant Haemophilus influenzae infections in Guangzhou, China.
Ann Clin Microbiol Antimicrob. 2018 Nov 23;17(1):41. doi: 10.1186/s12941-018-0290-9.
10
Conserved collateral antibiotic susceptibility networks in diverse clinical strains of Escherichia coli.
Nat Commun. 2018 Sep 10;9(1):3673. doi: 10.1038/s41467-018-06143-y.
本文引用的文献
1
Quinolone-resistant Haemophilus influenzae in a long-term-care facility: nucleotide sequence characterization of alterations in the genes encoding DNA gyrase and DNA topoisomerase IV.
Antimicrob Agents Chemother. 2004 Sep;48(9):3570-2. doi: 10.1128/AAC.48.9.3570-3572.2004.
2
In vitro activities of garenoxacin (BMS-284756) against Haemophilus influenzae isolates with different fluoroquinolone susceptibilities.
Antimicrob Agents Chemother. 2003 Nov;47(11):3539-41. doi: 10.1128/AAC.47.11.3539-3541.2003.
3
Fluoroquinolone resistance in Haemophilus influenzae.
J Antimicrob Chemother. 2003 Oct;52(4):734-5. doi: 10.1093/jac/dkg420. Epub 2003 Sep 1.
4
Five-year analysis of Haemophilus influenzae isolates with reduced susceptibility to fluoroquinolones: prevalence results from the SENTRY antimicrobial surveillance program.
Diagn Microbiol Infect Dis. 2003 May;46(1):55-61. doi: 10.1016/s0732-8893(03)00016-6.
5
Fluoroquinolones: action and resistance.
Curr Top Med Chem. 2003;3(3):249-82. doi: 10.2174/1568026033452537.
6
Activities of 13 quinolones by three susceptibility testing methods against a collection of Haemophilus influenzae isolates with different levels of susceptibility to ciprofloxacin: evidence for cross-resistance.
J Antimicrob Chemother. 2003 Jan;51(1):147-51. doi: 10.1093/jac/dkg049.
7
Selection of Streptococcus pneumoniae mutants having reduced susceptibility to moxifloxacin and levofloxacin.
Antimicrob Agents Chemother. 2002 Feb;46(2):522-4. doi: 10.1128/AAC.46.2.522-524.2002.
8
Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies.
Clin Infect Dis. 2001 Sep 15;33 Suppl 3:S147-56. doi: 10.1086/321841.
9
Pathogenesis and pathology of COPD.
Respiration. 2001;68(2):117-28. doi: 10.1159/000050478.
10
In vitro selection of fluoroquinolone-resistant Neisseria gonorrhoeae harboring alterations in DNA gyrase and topoisomerase IV.
J Urol. 2000 Sep;164(3 Pt 1):847-51. doi: 10.1097/00005392-200009010-00060.
Zotero 插件